Table 3 Post-discharge health expenditures per patient for hypoglycaemia-related outcomes
From: Cost burden and net monetary benefit loss of neonatal hypoglycaemia
Outcome | Outcome subgroup | Population | Cost components | Cost (per patient, mean annual, 2018 NZ$) |
|---|---|---|---|---|
Cerebral Palsy | All | Medicaid-enrolled patients < 17 years of age, United States | Total health care expenditure (inpatient costs, outpatient costs, medications), US$ (2005 data) | $41,332 [36] |
Cerebral palsy, no intellectual disability | $31,211 [36] | |||
Severe intellectual disorders/ learning disabilities | IQ 50–69 | Families with children with intellectual disability, Australia | Annual government assistance; out-of-pocket health and home care expenses, AU$ (2012 data) | $15,532 [37] |
IQ 35–49 | $25,317 [37] | |||
IQ < 35 | $17,857 [37] | |||
Epilepsy | Epilepsy | All patients, Australia | Direct health care costs (hospital costs, medication costs, other), US$ (1990 data) | $5196 [38] |
Vision disorders | Impaired visual acuity, mixed aetiologies | All patients, Australia | Total health-related cost (informal care and support; medicines, products, and equipment; health and community services; and other expenses), US$ (2009 data) | $3124 [39] |
Mixed aetiologies | All patients, Australia | Direct health system costs, based on health service utilisation, AU$ (2000–2004 data) | $5377 [40] |